Advances in research on biomaterials and stem cell/exosome-based strategies in the treatment of traumatic brain injury.
10.1016/j.apsb.2025.05.010
- Author:
Wenya CHI
1
;
Yingying HE
1
;
Shuisheng CHEN
1
;
Lingyi GUO
1
;
Yan YUAN
1
;
Rongjie LI
1
;
Ruiyao LIU
1
;
Dairan ZHOU
2
;
Jianzhong DU
3
;
Tao XU
2
;
Yuan YU
1
Author Information
1. Department of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. Department of Neurosurgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
3. Department of Gynaecology and Obstetrics, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
- Publication Type:Review
- Keywords:
Biomaterial;
Bioscaffold;
Exosome;
Extracellular matrix;
Nano-drug delivery system;
Regeneration;
Stem cell;
Traumatic brain injury
- From:
Acta Pharmaceutica Sinica B
2025;15(7):3511-3544
- CountryChina
- Language:English
-
Abstract:
Traumatic brain injury (TBI) is intricately linked to the most severe clinical manifestations of brain damage. It encompasses dynamic pathological mechanisms, including hemodynamic disorders, excitotoxic injury, oxidative stress, mitochondrial dysfunction, inflammation, and neuronal death. This review provides a comprehensive analysis and summary of biomaterial-based tissue engineering scaffolds and nano-drug delivery systems. As an example of functionalized biomaterials, nano-drug delivery systems alter the pharmacokinetic properties of drugs. They provide multiple targeting strategies relying on factors such as morphology and scale, magnetic fields, pH, photosensitivity, and enzymes to facilitate the transport of therapeutics across the blood-brain barrier and to promote selective accumulation at the injury site. Furthermore, therapeutic agents can be incorporated into bioscaffolds to interact with the biochemical and biophysical environment of the brain. Bioscaffolds can mimic the extracellular matrix environment, regulate cellular interactions, and increase the effectiveness of local treatments following surgical interventions. Additionally, stem cell-based and exosome-dominated extracellular vesicle carriers exhibit high bioreactivity and low immunogenicity and can be used to design therapeutic agents with high bioactivity. This review also examines the utilization of endogenous bioactive materials in the treatment of TBI.
